Kiniksa Pharmaceuticals Ltd (KNSA)
20.24
-0.09
(-0.44%)
USD |
NASDAQ |
May 08, 15:13
Kiniksa Pharmaceuticals Enterprise Value: 1.229B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 1.229B |
| May 06, 2024 | 1.205B |
| May 03, 2024 | 1.211B |
| May 02, 2024 | 1.161B |
| May 01, 2024 | 1.163B |
| April 30, 2024 | 1.114B |
| April 29, 2024 | 1.102B |
| April 26, 2024 | 1.055B |
| April 25, 2024 | 1.036B |
| April 24, 2024 | 1.053B |
| April 23, 2024 | 1.041B |
| April 22, 2024 | 999.17M |
| April 19, 2024 | 986.05M |
| April 18, 2024 | 983.90M |
| April 17, 2024 | 988.87M |
| April 16, 2024 | 1.025B |
| April 15, 2024 | 1.024B |
| April 12, 2024 | 1.011B |
| April 11, 2024 | 1.040B |
| April 10, 2024 | 1.022B |
| April 09, 2024 | 1.042B |
| April 08, 2024 | 1.039B |
| April 05, 2024 | 1.054B |
| April 04, 2024 | 1.065B |
| April 03, 2024 | 1.078B |
| Date | Value |
|---|---|
| April 02, 2024 | 1.113B |
| April 01, 2024 | 1.182B |
| March 31, 2024 | 1.184B |
| March 28, 2024 | 1.187B |
| March 27, 2024 | 1.205B |
| March 26, 2024 | 1.204B |
| March 25, 2024 | 1.203B |
| March 22, 2024 | 1.204B |
| March 21, 2024 | 1.192B |
| March 20, 2024 | 1.190B |
| March 19, 2024 | 1.185B |
| March 18, 2024 | 1.176B |
| March 15, 2024 | 1.205B |
| March 14, 2024 | 1.231B |
| March 13, 2024 | 1.238B |
| March 12, 2024 | 1.237B |
| March 11, 2024 | 1.230B |
| March 08, 2024 | 1.263B |
| March 07, 2024 | 1.295B |
| March 06, 2024 | 1.277B |
| March 05, 2024 | 1.219B |
| March 04, 2024 | 1.219B |
| March 01, 2024 | 1.329B |
| February 29, 2024 | 1.286B |
| February 28, 2024 | 1.231B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
28.78M
Minimum
Oct 18 2019
1.329B
Maximum
Mar 01 2024
748.02M
Average
744.56M
Median
Jun 16 2021
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.177B |
| Geron Corp | 1.929B |
| United Therapeutics Corp | 9.709B |
| Vanda Pharmaceuticals Inc | -73.53M |
| TG Therapeutics Inc | 2.444B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.70M |
| Revenue (Quarterly) | 79.86M |
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.25 |
| Gross Profit Margin (Quarterly) | 60.70% |
| Profit Margin (Quarterly) | -22.17% |
| Earnings Yield | 0.54% |
| Normalized Earnings Yield | 0.5435 |